Racial disparities in the management of hospitalized patients with cirrhosis and portal hypertension

Abstract

HCC, we agree with Sangiovanni and Iavarone that similar ultrasound surveillance intervals appear to be adequate for both patient groups, as recommended by international guidelines. Still, clinicians should be aware of the potentially higher oncogenic risk of genotype 1b in addition to other recognized risk factors and, to this end, it would be reasonable to recommend a more careful follow-up of these patients. This concept is strengthened by recent evidence showing that specific conformational features of the secondary structure of the N-terminus of the NS3 protein, characteristics of certain strains of HCV type 1b, are associated with an increased risk of HCC, 3 thus providing a plausible pathogenetic basis for our findings.

Morbidity and mortality following coronary artery bypass graft surgery in patients with cirrhosis: a population‐based study

“…Four cardiovascular conditions (congestive heart failure, arrhythmia, cardiac valvular disorders and pulmonary circulation disorders) and coagulopathy were excluded from this algorithm and analysed separately; the remaining comorbidities were categorized as 0, 1, 2 and ≥3. As liver disease severity is an important predictor of post‐operative mortality and laboratory data are not available in the NIS for calculation of the CP or model for end‐stage liver disease (MELD) scores (12, 20), we also controlled for features of hepatic decompensation using ICD‐9‐CM diagnosis codes as described previously (21, 22). There is no standard definition for coagulopathy in the ICD‐9‐CM coding system, thus making this an arbitrary distinction.…”